Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Prime Medicine, Inc. Common Stock

Healthcare US PRME

3.06USD
-0.41(11.82%)

Last update at 2026-06-05T20:25:00Z

Day Range

2.943.44
LowHigh

52 Week Range

4.1117.20
LowHigh

Fundamentals

  • Previous Close 3.47
  • Market Cap780.20M
  • Volume4480882
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-194.68400M
  • Revenue TTM0.59M
  • Revenue Per Share TTM0.006
  • Gross Profit TTM -86.72500M
  • Diluted EPS TTM-2.05

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -122.76900M -165.85300M -1.54300M -
Minority interest - - - -
Net income -121.82100M -165.36700M -3.41000M -
Selling general administrative 29.82M 13.92M 3.16M -
Selling and marketing expenses - - - -
Gross profit 5.21M - 5.21M -
Reconciled depreciation 2.22M 0.57M 0.04M -
Ebit -116.54400M -84.47400M -0.93200M -6.51600M
Ebitda -108.41600M -83.51500M -11.75600M -
Depreciation and amortization 8.13M 0.96M -10.82400M -
Non operating income net other -6.22500M - - -
Operating income -116.54400M -84.47400M -0.93200M -
Other operating expenses 116.54M 84.47M 6.14M -
Interest expense 12.13M 81.77M 10.26M -
Tax provision -0.94800M -0.48600M 1.87M -
Interest income - - - -
Net interest income - - - -
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense -0.94800M -0.48600M 1.87M 0.01M
Total revenue 5.21M 0.00000M 5.21M -
Total operating expenses 116.54M 84.47M 6.14M -
Cost of revenue - - - -
Total other income expense net -6.22500M -81.37900M -0.61100M -
Discontinued operations - - - -
Net income from continuing ops -121.82100M -165.36700M -3.41000M -
Net income applicable to common shares -142.01400M -184.11900M -5.05500M -8.38200M
Preferred stock and other adjustments 20.19M - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 193.85M 360.31M 301.86M 54.78M -
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 2.25M 2.70M 0.96M 0.07M -
Total liab 60.78M 360.31M 62.30M 21.31M -
Total stockholder equity 133.07M -293.58100M 239.56M 33.47M -
Deferred long term liab - - - - -
Other current liab 1.60M 10.69M 12.30M 19.19M 6.77M
Common stock 0.00200M 0.00200M - - 0.00100M
Capital stock 0.00200M 0.00200M 395.80M 31.14M -
Retained earnings -491.33000M -293.19700M -171.37600M -6.00900M -2.59900M
Other liab - 0.28M 1.24M 1.87M -
Good will - - - - -
Other assets - 15.14M 15.60M 0.79M -
Cash 41.57M 187.62M 185.42M 36.98M -
Cash and equivalents - - - - -
Total current liabilities 56.42M 26.71M 57.98M 19.44M 7.31M
Current deferred revenue 26.00M - 36.91M - -
Net debt -27.94100M -158.87500M -175.01400M -36.97500M -
Short term debt 9.28M 11.69M 7.34M - -
Short long term debt - - - - -
Short long term debt total 13.63M 28.75M 10.41M - -
Other stockholder equity 624.41M -360.31600M 15.16M 8.35M -
Property plant equipment - 19.01M 15.68M 0.60M -
Total current assets 142.98M 293.92M 270.58M 53.40M 8.70M
Long term investments - - - - -
Net tangible assets - 316.27M -156.24000M 2.34M -2.59800M
Short term investments 80.09M 106.30M 84.20M 16.35M -
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 19.54M 4.33M 1.44M 0.25M -
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.01500M -0.38400M -0.02700M - -
Additional paid in capital - - - - -
Common stock total equity - 0.00200M - - -
Preferred stock total equity - - - - -
Retained earnings total equity - -293.19700M - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 19.73M -52.76100M 15.60M 0.79M -
Deferred long term asset charges - - - - -
Non current assets total 50.88M 66.39M 31.28M 1.38M -
Capital lease obligations 13.63M 28.75M 10.41M 0.00000M -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -30.33600M -68.98000M -68.98000M -68.98000M
Change to liabilities -23.41500M 1.19M 0.25M 0.00000M
Total cashflows from investing activities -47.09600M -73.62600M -1.06200M -1.06200M
Net borrowings - - - -
Total cash from financing activities 181.49M 269.28M 34.93M 29.94M
Change to operating activities -37.85900M 29.99M -0.08600M 1.48M
Net income -121.82100M -165.36700M -3.41000M -7.58700M
Change in cash 2.57M 161.57M 28.33M 25.94M
Begin period cash flow 198.54M 36.98M 8.65M -
End period cash flow 201.12M 198.54M 36.98M 8.65M
Total cash from operating activities -131.82700M -34.08200M -5.54400M -4.00200M
Issuance of capital stock 185.32M 270.36M 34.95M -
Depreciation 2.22M 0.57M 0.04M 0.04M
Other cashflows from investing activities -0.66500M -0.49600M -0.42300M -0.42300M
Dividends paid - - - -
Change to inventory - - - -
Change to account receivables - - - -
Sale purchase of stock 181.49M - - -
Other cashflows from financing activities -3.82300M 269.28M 34.93M -0.02000M
Change to netincome 5.50M 99.54M -2.34100M 2.11M
Capital expenditures 16.09M 4.15M 0.64M 0.64M
Change receivables - - - -
Cash flows other operating 5.93M - - -
Exchange rate changes - - - -
Cash and cash equivalents changes 2.57M - - -
Change in working capital -35.40100M 31.18M 0.16M -
Stock based compensation 6.46M 1.75M 0.39M -
Other non cash items 17.68M 98.42M -4.59900M -
Free cash flow -147.92200M -38.23200M -6.18300M -

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
PRME
Prime Medicine, Inc. Common Stock		 -0.41 11.82% 3.06 - - - 5.17 -3.1034
NVO
Novo Nordisk A/S		 -0.79 1.81% 42.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.09 1.15% 446.83 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.72 1.07% 635.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.

Prime Medicine, Inc. Common Stock

21 Erie Street, Cambridge, MA, United States, 02139

Key Executives

Name Title Year Born
Dr. Keith Michael Gottesdiener M.D. Pres, CEO, Sec. & Director 1954
Dr. Ann L. Lee Ph.D. Chief Technical Officer 1962
Dr. Jeremy S. Duffield M.D., Ph.D. Chief Scientific Officer 1968
Dr. Andrew Anzalone M.D., Ph.D. Co-Founder, Sr. Scientist II, Head of Prime Editing Platform & Head of Platform Devel. 1986
Dr. David R. Liu Ph.D. Co-Founder & Chair of Scientific Advisory Board NA
Ms. Carman Alenson CPA, M.B.A. Chief Accounting Officer & Interim CFO 1965
Dr. Meredith Goldwasser Sr. VP of Strategy & Corp. Operations and Head of Strategy & Corp. Operations 1971
Dr. Karen Brown J.D., Ph.D. Sr. VP of Intellectual Property & Legal Affairs NA
Ms. Niamh Alix Chief HR Officer NA
Mr. Richard Brudnick Chief Bus. Officer 1957

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.